425: CoreWeave Files SEC Form 425 on Proposed Core Scientific Acquisition, Urges Investor Review of Transaction Details

CoreWeave, Inc. has filed a Form 425 communication with the SEC regarding its proposed acquisition of Core Scientific, Inc., emphasizing the importance for investors to review comprehensive transaction documents.

Summary

• CoreWeave, Inc. filed a Form 425 communication with the U.S. Securities and Exchange Commission (SEC) on July 14, 2025, related to its proposed acquisition of Core Scientific, Inc.
• The communication, originally posted on CoreWeave's X account on July 11, 2025, serves to inform stakeholders about the transaction.
• CoreWeave and Core Scientific will file relevant materials with the SEC, including a registration statement on Form S-4 by CoreWeave, which will incorporate a proxy statement of Core Scientific and a prospectus of CoreWeave.
• Investors and security holders are strongly urged to read the registration statement, proxy statement/prospectus, and all other relevant documents filed with the SEC carefully and in their entirety when they become available, as they contain important information about the proposed transaction.
• Free copies of these documents will be available on the SEC's website, and on the respective investor relations websites of CoreWeave and Core Scientific.
• The filing clarifies that this communication is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor a solicitation of any vote or approval.
• The document includes extensive forward-looking statements, highlighting various risks and uncertainties that could cause actual results to differ materially from expectations regarding the transaction.

Sentiment

Score: 5

Explanation: The document is a neutral, procedural SEC filing primarily focused on disclosure requirements and risk factors related to a proposed acquisition, rather than presenting financial performance or operational updates.

Risks

• Completion of the proposed transaction on anticipated terms, or at all, and the timing of completion, including obtaining required regulatory approvals and Core Scientific stockholder approval.
• Unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies for the combined company's operations.
• The possibility that any anticipated benefits of the proposed transaction will not be realized or will not be realized within the expected time period.
• The ability of CoreWeave and Core Scientific to integrate their businesses successfully and to achieve anticipated synergies and value creation.
• Potential litigation relating to the proposed transaction that could be instituted against CoreWeave, Core Scientific, or their respective directors and officers.
• Disruptions from the proposed transaction harming CoreWeave's or Core Scientific's business, including current plans and operations.
• Management's time and attention being diverted on transaction-related issues.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transaction.
• Rating agency actions and CoreWeave's and Core Scientific's ability to access shortand long-term debt markets on a timely and affordable basis.
• Legislative, regulatory, and economic developments and actions targeting public companies in the artificial intelligence, power, data center, and crypto mining industries.
• Changes in local, national, or international laws, regulations, and policies affecting CoreWeave and Core Scientific.
• Potential business uncertainty, including the outcome of commercial negotiations and changes to existing business relationships during the pendency of the proposed transaction.
• Certain restrictions during the pendency of the proposed transaction that may impact Core Scientific's ability to pursue certain business opportunities or strategic transactions or otherwise operate its business.
• Acts of terrorism or outbreak of war, hostilities, civil unrest, attacks against CoreWeave or Core Scientific, and other political or security disturbances.
• Dilution caused by CoreWeave's issuance of additional shares of its securities in connection with the proposed transaction.
• The possibility that the transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events.
• The impacts of pandemics or other public health crises, including the effects of government responses on people and economies.
• Global or regional changes in the supply and demand for power and other market or economic conditions that impact demand and pricing.
• Changes in technical or operating conditions, including unforeseen technical difficulties.
• Development delays at CoreWeave and/or Core Scientific data center sites, including any delays in the conversion of such sites from crypto mining facilities to high-performance computing sites.
• Risks described in CoreWeave's Prospectus dated March 27, 2025, and subsequent reports on Forms 10-Q and 8-K.
• Risks described in Core Scientific's Quarterly Report on Form 10-Q for the period ended March 31, 2025, Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent reports on Forms 10-Q and 8-K.
• Risks that will be described in the registration statement on Form S-4 and accompanying prospectus.

Future Outlook

Forward-looking statements address the consummation of the proposed transaction and its anticipated benefits, acknowledging that actual results may differ materially due to various risks, uncertainties, and assumptions. The companies do not assume any obligation to publicly update these statements unless required by law.

Management Comments

• CoreWeave emphasizes the importance for investors and security holders of both CoreWeave and Core Scientific to thoroughly read the registration statement, proxy statement/prospectus, and all other relevant documents filed with the SEC when they become available, as they will contain critical information about the proposed transaction and related matters.

Industry Context

The proposed acquisition involves companies operating in the artificial intelligence, power, data center, and crypto mining industries. A key industry trend highlighted is the potential conversion of crypto mining facilities to high-performance computing sites, which is a strategic focus for the combined entity.

Legal Proceedings

• Potential litigation relating to the proposed transaction could be instituted against CoreWeave, Core Scientific, or their respective directors and officers.

Stakeholder Impact

• Shareholders of Core Scientific will be required to vote on the proposed transaction.
• Shareholders of CoreWeave may experience dilution due to the issuance of additional shares in connection with the transaction.
• Employees of both companies may be impacted by business integration efforts.
• Customers and suppliers may experience changes to business relationships as a result of the announcement or completion of the proposed transaction.

Next Steps

• CoreWeave and Core Scientific will file a registration statement on Form S-4, including a proxy statement/prospectus, with the SEC.
• A definitive proxy statement/prospectus will be mailed to stockholders of Core Scientific.
• Core Scientific stockholder approval for the proposed transaction is required.
• Regulatory approvals may be required for the completion of the transaction.
• CoreWeave and Core Scientific aim to integrate their businesses successfully and achieve anticipated synergies and value creation.

Key Dates

Keywords

CoreWeave, Core Scientific, acquisition, merger, SEC filing, Form 425, Form S-4, proxy statement, prospectus, artificial intelligence, data center, high-performance computing, crypto mining, corporate transaction